Shares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came ...

Short seller Scorpion Capital disclosed a short position in TransMedics Group Inc (NASDAQ:TMDX) accusing the organ transplant tech. company of fraudulent practices, including kickbacks, billing fraud, ...

EST TransMedics (TMDX) down 10% to $65.39 after Scorpion Capital short reportStay Ahead of the Market:Discover outperforming stocks and ...

Scorpion Capital said in a newly-issued short report that in “20 years of shorting, TransMedics (TMDX) is the most extreme and grotesque ...

The report further alleges that TransMedics has been involved in kickbacks, billing fraud, unreported device failures, and ...

NDAQ:TMDX) Kehoe Law Firm, P.C. Securities Investigation on Behalf of Investors of TransMedics Group Stock Following Critical Report - NASDAQ: TMDX ...

Eli Lilly in talks to acquire cancer biotech Scorpion Therapeutics for $2.5 billion, with potential milestone payments.

TransMedics is a commercial-stage medical technology company working on organ transplant therapy. Check out more about the ...

Transmedics replaced its CFO in early December. Management also narrowed fourth-quarter guidance to the lower half of the previous range. Can Transmedics reaccelerate growth after this slowdown ...

TransMedics Group, Inc. (NASDAQ:TMDX), a leading player in the organ transplant technology sector with a market capitalization of $2.55 billion, has been making waves in the medical device ...